Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al
Arthritis & Rheumatology · 2023
DOI: 10.1002/art.42379 ↗Kurz gefasst
Leserbrief in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Hanlin Yin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Botulinum Toxins, Raynaud Disease, Scleroderma, Systemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Hanlin Yin, Qingran Yan, Liangjing Lu
Zitieren
APA
Yin, H., Liu, B., Li, Q., Yan, Q., & Lu, L. (2023). Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al. Arthritis & Rheumatology. https://doi.org/10.1002/art.42379
Vancouver
Yin H, Liu B, Li Q, Yan Q, Lu L. Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al. Arthritis & Rheumatology. 2023. doi:10.1002/art.42379
BibTeX
@article{Yin2023,
author = {Yin, Hanlin and Liu, Bei and Li, Qianqian and Yan, Qingran and Lu, Liangjing},
title = {Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al},
journal = {Arthritis & Rheumatology},
year = {2023},
doi = {10.1002/art.42379}
}
EUVIMED